Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b

BACKGROUND: Decreased hemoglobin (Hb) level has been supposed to be a relatively rare side effect of a combination therapy against hepatitis C virus that consists of the NS5A inhibitor daclatasvir (DCV) and the NS3/4A protease inhibitor asunaprevir (ASV). METHODS: The study was conducted in 75 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Nobuyuki, Ikeda, Hiroki, Shigefuku, Ryuta, Hattori, Nobuhiro, Watanabe, Tsunamasa, Matsunaga, Kotaro, Hiraishi, Tetsuya, Tamura, Tomohiro, Noguchi, Yohei, Fukuda, Yasunobu, Ishii, Toshiya, Okuse, Chiaki, Sato, Akira, Suzuki, Michihiro, Itoh, Fumio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798293/
https://www.ncbi.nlm.nih.gov/pubmed/26990758
http://dx.doi.org/10.1371/journal.pone.0151238
Descripción
Sumario:BACKGROUND: Decreased hemoglobin (Hb) level has been supposed to be a relatively rare side effect of a combination therapy against hepatitis C virus that consists of the NS5A inhibitor daclatasvir (DCV) and the NS3/4A protease inhibitor asunaprevir (ASV). METHODS: The study was conducted in 75 patients with genotype 1b chronic hepatitis C virus infection who had started combination therapy with DCV and ASV at St. Marianna University School of Medicine Hospital between September 2014 and December 2014. RESULTS: Among the patients examined, decreased Hb level by ≥1.5 g/dL from the values at treatment initiation was observed in 11 individuals. This was accompanied by decreased mean corpuscular volume, and iron and ferritin levels. CONCLUSIONS: These findings suggest that the mechanism of the phenomenon is caused by iron deficiency. The underlying mechanism and clinical impacts will need to be further examined.

Ejemplares similares